{"id":23630,"date":"2022-03-24T09:32:26","date_gmt":"2022-03-24T09:32:26","guid":{"rendered":"https:\/\/celonpharma.com\/?p=23630"},"modified":"2022-05-24T12:04:17","modified_gmt":"2022-05-24T12:04:17","slug":"february-16-2022-current-report-no-4-2022-the-kdpw-statement-on-concluding-an-agreement-on-the-registration-of-the-companys-series-c-shares","status":"publish","type":"post","link":"https:\/\/celonpharma.com\/en\/february-16-2022-current-report-no-4-2022-the-kdpw-statement-on-concluding-an-agreement-on-the-registration-of-the-companys-series-c-shares\/","title":{"rendered":"February 16, 2022 \u2013 Current Report No. 4\/2022 \u2013 The KDPW statement on concluding an agreement on the registration of the Company’s series C shares"},"content":{"rendered":"\n

Legal basis: Article 56 section 1 point 2 Act on Public Offering \u2013 current and periodic information.
Date: February 16, 2022.
The abbreviated name of the issuer CELON PHARMA S.A.
Subject: The KDPW statement on concluding an agreement on the registration of the Company’s series C shares<\/p>\n\n\n\n

The Management Board of Celon Pharma SA (the “Company”) hereby informs about the statement issued by the Central Securities Depository of Poland (“KDPW”), on February 15, 2022, on conclusion of an agreement with the Company on the registration of securities in the depository of up to 2,000,000 series C shares of the Company.
Th shares will be registered on the basis of settlement orders referred to in \u00a7 6 of the Specific Operating Rules, in connection with deregistration of subscription warrants which were used to exercise the rights of the above-mentioned shares.
Series C shares are issued as part of the contingent capital, pursuant to Resolution No. 7\/2021of the General Meeting of Shareholders of February 16, 2021 (current report No. 9\/2021).<\/p>\n","protected":false},"excerpt":{"rendered":"

Legal basis: Article 56 section 1 point 2 Act on Public Offering \u2013 current and periodic information.Date: February 16, 2022.The abbreviated name of the issuer CELON PHARMA S.A.Subject: The KDPW statement on concluding an agreement on the registration of the Company’s series C shares The Management Board of Celon Pharma SA (the “Company”) hereby informsRead more »<\/a><\/p>\n","protected":false},"author":31,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"footnotes":""},"categories":[30,46],"tags":[],"class_list":["post-23630","post","type-post","status-publish","format-standard","hentry","category-general-en","category-current-reports"],"acf":[],"yoast_head":"\nFebruary 16, 2022 \u2013 Current Report No. 4\/2022 \u2013 The KDPW statement on concluding an agreement on the registration of the Company's series C shares - Celon Pharma<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/celonpharma.com\/en\/february-16-2022-current-report-no-4-2022-the-kdpw-statement-on-concluding-an-agreement-on-the-registration-of-the-companys-series-c-shares\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"February 16, 2022 \u2013 Current Report No. 4\/2022 \u2013 The KDPW statement on concluding an agreement on the registration of the Company's series C shares - Celon Pharma\" \/>\n<meta property=\"og:description\" content=\"Legal basis: Article 56 section 1 point 2 Act on Public Offering \u2013 current and periodic information.Date: February 16, 2022.The abbreviated name of the issuer CELON PHARMA S.A.Subject: The KDPW statement on concluding an agreement on the registration of the Company’s series C shares The Management Board of Celon Pharma SA (the “Company”) hereby informsRead more »\" \/>\n<meta property=\"og:url\" content=\"https:\/\/celonpharma.com\/en\/february-16-2022-current-report-no-4-2022-the-kdpw-statement-on-concluding-an-agreement-on-the-registration-of-the-companys-series-c-shares\/\" \/>\n<meta property=\"og:site_name\" content=\"Celon Pharma\" \/>\n<meta property=\"article:published_time\" content=\"2022-03-24T09:32:26+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2022-05-24T12:04:17+00:00\" \/>\n<meta name=\"author\" content=\"Paulina Dobies\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Paulina Dobies\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/celonpharma.com\\\/en\\\/february-16-2022-current-report-no-4-2022-the-kdpw-statement-on-concluding-an-agreement-on-the-registration-of-the-companys-series-c-shares\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/celonpharma.com\\\/en\\\/february-16-2022-current-report-no-4-2022-the-kdpw-statement-on-concluding-an-agreement-on-the-registration-of-the-companys-series-c-shares\\\/\"},\"author\":{\"name\":\"Paulina Dobies\",\"@id\":\"https:\\\/\\\/celonpharma.com\\\/en\\\/#\\\/schema\\\/person\\\/e86806fa37010f6a01f6fc388950174b\"},\"headline\":\"February 16, 2022 \u2013 Current Report No. 4\\\/2022 \u2013 The KDPW statement on concluding an agreement on the registration of the Company’s series C shares\",\"datePublished\":\"2022-03-24T09:32:26+00:00\",\"dateModified\":\"2022-05-24T12:04:17+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/celonpharma.com\\\/en\\\/february-16-2022-current-report-no-4-2022-the-kdpw-statement-on-concluding-an-agreement-on-the-registration-of-the-companys-series-c-shares\\\/\"},\"wordCount\":177,\"articleSection\":[\"News\",\"Current reports\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/celonpharma.com\\\/en\\\/february-16-2022-current-report-no-4-2022-the-kdpw-statement-on-concluding-an-agreement-on-the-registration-of-the-companys-series-c-shares\\\/\",\"url\":\"https:\\\/\\\/celonpharma.com\\\/en\\\/february-16-2022-current-report-no-4-2022-the-kdpw-statement-on-concluding-an-agreement-on-the-registration-of-the-companys-series-c-shares\\\/\",\"name\":\"February 16, 2022 \u2013 Current Report No. 4\\\/2022 \u2013 The KDPW statement on concluding an agreement on the registration of the Company's series C shares - Celon Pharma\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/celonpharma.com\\\/en\\\/#website\"},\"datePublished\":\"2022-03-24T09:32:26+00:00\",\"dateModified\":\"2022-05-24T12:04:17+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/celonpharma.com\\\/en\\\/#\\\/schema\\\/person\\\/e86806fa37010f6a01f6fc388950174b\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/celonpharma.com\\\/en\\\/february-16-2022-current-report-no-4-2022-the-kdpw-statement-on-concluding-an-agreement-on-the-registration-of-the-companys-series-c-shares\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/celonpharma.com\\\/en\\\/february-16-2022-current-report-no-4-2022-the-kdpw-statement-on-concluding-an-agreement-on-the-registration-of-the-companys-series-c-shares\\\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/celonpharma.com\\\/en\\\/february-16-2022-current-report-no-4-2022-the-kdpw-statement-on-concluding-an-agreement-on-the-registration-of-the-companys-series-c-shares\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/celonpharma.com\\\/en\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"February 16, 2022 \u2013 Current Report No. 4\\\/2022 \u2013 The KDPW statement on concluding an agreement on the registration of the Company’s series C shares\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/celonpharma.com\\\/en\\\/#website\",\"url\":\"https:\\\/\\\/celonpharma.com\\\/en\\\/\",\"name\":\"Celon Pharma\",\"description\":\"\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/celonpharma.com\\\/en\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/celonpharma.com\\\/en\\\/#\\\/schema\\\/person\\\/e86806fa37010f6a01f6fc388950174b\",\"name\":\"Paulina Dobies\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"February 16, 2022 \u2013 Current Report No. 4\/2022 \u2013 The KDPW statement on concluding an agreement on the registration of the Company's series C shares - Celon Pharma","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/celonpharma.com\/en\/february-16-2022-current-report-no-4-2022-the-kdpw-statement-on-concluding-an-agreement-on-the-registration-of-the-companys-series-c-shares\/","og_locale":"en_US","og_type":"article","og_title":"February 16, 2022 \u2013 Current Report No. 4\/2022 \u2013 The KDPW statement on concluding an agreement on the registration of the Company's series C shares - Celon Pharma","og_description":"Legal basis: Article 56 section 1 point 2 Act on Public Offering \u2013 current and periodic information.Date: February 16, 2022.The abbreviated name of the issuer CELON PHARMA S.A.Subject: The KDPW statement on concluding an agreement on the registration of the Company’s series C shares The Management Board of Celon Pharma SA (the “Company”) hereby informsRead more »","og_url":"https:\/\/celonpharma.com\/en\/february-16-2022-current-report-no-4-2022-the-kdpw-statement-on-concluding-an-agreement-on-the-registration-of-the-companys-series-c-shares\/","og_site_name":"Celon Pharma","article_published_time":"2022-03-24T09:32:26+00:00","article_modified_time":"2022-05-24T12:04:17+00:00","author":"Paulina Dobies","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Paulina Dobies","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/celonpharma.com\/en\/february-16-2022-current-report-no-4-2022-the-kdpw-statement-on-concluding-an-agreement-on-the-registration-of-the-companys-series-c-shares\/#article","isPartOf":{"@id":"https:\/\/celonpharma.com\/en\/february-16-2022-current-report-no-4-2022-the-kdpw-statement-on-concluding-an-agreement-on-the-registration-of-the-companys-series-c-shares\/"},"author":{"name":"Paulina Dobies","@id":"https:\/\/celonpharma.com\/en\/#\/schema\/person\/e86806fa37010f6a01f6fc388950174b"},"headline":"February 16, 2022 \u2013 Current Report No. 4\/2022 \u2013 The KDPW statement on concluding an agreement on the registration of the Company’s series C shares","datePublished":"2022-03-24T09:32:26+00:00","dateModified":"2022-05-24T12:04:17+00:00","mainEntityOfPage":{"@id":"https:\/\/celonpharma.com\/en\/february-16-2022-current-report-no-4-2022-the-kdpw-statement-on-concluding-an-agreement-on-the-registration-of-the-companys-series-c-shares\/"},"wordCount":177,"articleSection":["News","Current reports"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/celonpharma.com\/en\/february-16-2022-current-report-no-4-2022-the-kdpw-statement-on-concluding-an-agreement-on-the-registration-of-the-companys-series-c-shares\/","url":"https:\/\/celonpharma.com\/en\/february-16-2022-current-report-no-4-2022-the-kdpw-statement-on-concluding-an-agreement-on-the-registration-of-the-companys-series-c-shares\/","name":"February 16, 2022 \u2013 Current Report No. 4\/2022 \u2013 The KDPW statement on concluding an agreement on the registration of the Company's series C shares - Celon Pharma","isPartOf":{"@id":"https:\/\/celonpharma.com\/en\/#website"},"datePublished":"2022-03-24T09:32:26+00:00","dateModified":"2022-05-24T12:04:17+00:00","author":{"@id":"https:\/\/celonpharma.com\/en\/#\/schema\/person\/e86806fa37010f6a01f6fc388950174b"},"breadcrumb":{"@id":"https:\/\/celonpharma.com\/en\/february-16-2022-current-report-no-4-2022-the-kdpw-statement-on-concluding-an-agreement-on-the-registration-of-the-companys-series-c-shares\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/celonpharma.com\/en\/february-16-2022-current-report-no-4-2022-the-kdpw-statement-on-concluding-an-agreement-on-the-registration-of-the-companys-series-c-shares\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/celonpharma.com\/en\/february-16-2022-current-report-no-4-2022-the-kdpw-statement-on-concluding-an-agreement-on-the-registration-of-the-companys-series-c-shares\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/celonpharma.com\/en\/"},{"@type":"ListItem","position":2,"name":"February 16, 2022 \u2013 Current Report No. 4\/2022 \u2013 The KDPW statement on concluding an agreement on the registration of the Company’s series C shares"}]},{"@type":"WebSite","@id":"https:\/\/celonpharma.com\/en\/#website","url":"https:\/\/celonpharma.com\/en\/","name":"Celon Pharma","description":"","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/celonpharma.com\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/celonpharma.com\/en\/#\/schema\/person\/e86806fa37010f6a01f6fc388950174b","name":"Paulina Dobies"}]}},"_links":{"self":[{"href":"https:\/\/celonpharma.com\/en\/wp-json\/wp\/v2\/posts\/23630","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/celonpharma.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/celonpharma.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/celonpharma.com\/en\/wp-json\/wp\/v2\/users\/31"}],"replies":[{"embeddable":true,"href":"https:\/\/celonpharma.com\/en\/wp-json\/wp\/v2\/comments?post=23630"}],"version-history":[{"count":1,"href":"https:\/\/celonpharma.com\/en\/wp-json\/wp\/v2\/posts\/23630\/revisions"}],"predecessor-version":[{"id":23631,"href":"https:\/\/celonpharma.com\/en\/wp-json\/wp\/v2\/posts\/23630\/revisions\/23631"}],"wp:attachment":[{"href":"https:\/\/celonpharma.com\/en\/wp-json\/wp\/v2\/media?parent=23630"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/celonpharma.com\/en\/wp-json\/wp\/v2\/categories?post=23630"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/celonpharma.com\/en\/wp-json\/wp\/v2\/tags?post=23630"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}